Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B Mechanism Of Action At The Heart Of Panel Labeling Debate

This article was originally published in The Tan Sheet

Executive Summary

Women who are considering using Barr Laboratories' Plan B (levonorgestrel .75 mg) should know the drug's mechanism of action at the point of purchase, according to FDA advisory committee panelists

You may also be interested in...



Barr Plans Move To OTC Market With Plan B Emergency Contraceptive

Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product

WCC Plan B OTC Marketing Partnership Sought Pending Switch Approval

Women's Capital Corporation "is in discussions with a number of potential strategic marketers" to sell an OTC version of its Plan B emergency contraceptive pending approval of the firm's April 21 switch application

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS096304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel